A
AVIR
Atea Pharmaceuticals, Inc.
5.43
+0.07+1.31%After Hours: 5.43 0.00 0.00%19:30 08/21 EDT
OPEN/PREV CLOSE5.39/5.43
TODAY RANGE5.25-5.53
VOL99.43K
MARKET CAP441.93M
52 WEEK RANGE2.780-6.45
AVG VOL (3M)333.66K
% TURNOVER0.12%
TURNOVER--
P/E (TTM)-2.6345
% RANGE5.16%
EPS(TTM)-2.0915
P/E(FORWARD)-3.1307
P/B2.165
BVPS2.546
DIVIDEND--
P/S0.8414
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP381.86M
SHARES OUTSTANDING80.20M
NEXT EARNINGS11/10-11/16
FREE FLOAT69.30M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·21h ago
Atea Pharmaceuticals Eyes 2028 Launch After Strong Phase 3
Dow Jones·08/13 14:25
Atea Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones·08/13 14:25
Atea Pharmaceuticals Price Target Raised to $7.00/Share From $6.00 by Morgan Stanley
TipRanks·08/13 11:56
Atea Pharmaceuticals (AVIR) Receives a Hold from Morgan Stanley
Seeking Alpha·08/12 20:15
Atea Pharmaceuticals GAAP EPS of -$0.41 beats by $0.15
Dow Jones·08/12 20:05
Press Release: Atea Pharmaceuticals Reports -2-
Seeking Alpha·08/12 14:00
Here are the major earnings after the close Wednesday
Seeking Alpha·07/28 15:50
Atea drops despite late-stage trial win for hepatitis C therapy
Benzinga·07/28 14:13
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
Dow Jones·07/28 11:41
Atea Pharmaceuticals Shares Positive Results from Hepatitis C Trial
TipRanks·07/28 11:21
Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints
Same Industry
Name/Symbol
Change%
Price